Dr. Reddy's Laboratories Limited (DRREDDY)
ISIN: - Industry: Drug Manufacturers—Specialty & Generic Sector: Healthcare Website
4356.2
-5.3(-0.12%)

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Pricing Updates

TODAY'S HIGH

4379.25

TODAY'S LOW

4331.35

52 WEEK HIGH

4931.05

52 WEEK LOW

3654

Major Holders

% of Shares Held by
All Insider

8.57%

% of Shares Held by
Institutions

74.10%

% of Float Held by
Institutions

81.04%

Number of Institutions
Holding Shares

184

Company Overview

MARKET CAP

72326.85 Cr.

ETERPRISE VALUE

71380.17 Cr.

NO. OF SHARES

16.60 Cr.

BOOK VALUE

1242.184

DIV. YIELD

30%

DEBT

1728.90 Cr.

GROSS PROFIT

11384 Cr.

CASH

2757.49 Cr.

REVENUE

22277.60 Cr.

REVENUE/SHARE

1342.35

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Investments-1120.10 Cr.411 Cr.-21.40 Cr.-228.20 Cr.
Change To Liabilities441.20 Cr.286.10 Cr.157.60 Cr.39.80 Cr.
Total cashflows from Investing Activities-2638.70 Cr.-2266 Cr.-492.30 Cr.-772.70 Cr.
Net Borrowings273.50 Cr.609.40 Cr.-1916.50 Cr.-1518.20 Cr.
Total Cash from Financing Activities-242.20 Cr.-29.80 Cr.-2515.90 Cr.-2132.60 Cr.
Other Liabilities401.40 Cr.-325.80 Cr.482.10 Cr.412.20 Cr.
Total Assets33.40 Cr.26.90 Cr.40 Lakhs40 Lakhs
Net Income2356.80 Cr.1723.80 Cr.1949.80 Cr.1879.50 Cr.
Change in Cash3.20 Cr.1285.80 Cr.-26.60 Cr.-31.40 Cr.
Effect of Exchange Rate73.30 Cr.11.30 Cr.-2.50 Cr.3.50 Cr.
Total Cash from Operating Activities2810.80 Cr.3570.30 Cr.2984.10 Cr.2870.40 Cr.
Depreciation1182.40 Cr.1279.60 Cr.1247.20 Cr.1219 Cr.
Other Cashflows from Investing Activities87.30 Cr.122 Cr.101.60 Cr.78.10 Cr.
Dividends Paid-414.60 Cr.-414.70 Cr.-331.40 Cr.-332 Cr.
Change to Inventory-532.80 Cr.-988.10 Cr.-148.70 Cr.-448 Cr.
Change to Account Receivables-1701.20 Cr.208.10 Cr.-1244.60 Cr.179.70 Cr.
Other Cashflows from Financing Activities-134.50 Cr.-132.10 Cr.-221 Cr.-228.90 Cr.
Change to Net Income663 Cr.1386.60 Cr.540.70 Cr.-411.80 Cr.
Capital Expenditures-1466 Cr.-974.10 Cr.-484.60 Cr.-695.50 Cr.

Financials

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Research Development1748.20 Cr.1654.10 Cr.1541 Cr.1560.70 Cr.
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax3229.80 Cr.2641.30 Cr.1803.20 Cr.2244.30 Cr.
Minority InterestNoneNoneNoneNone
Net Income3151.60 Cr.3297 Cr.2931.30 Cr.1967.50 Cr.
Selling General Administrative6208.10 Cr.5459 Cr.5012.90 Cr.4868 Cr.
Gross Profit11384 Cr.10307.70 Cr.9400.90 Cr.8343 Cr.
Ebit3151.60 Cr.3297 Cr.2931.30 Cr.1967.50 Cr.
Operating Income3151.60 Cr.3297 Cr.2931.30 Cr.1967.50 Cr.
Other Operating Expenses276.10 Cr.-102.40 Cr.-84.30 Cr.-53.20 Cr.
Interest Expense-95.80 Cr.-97 Cr.-98.30 Cr.-88.90 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense873 Cr.917.50 Cr.-146.60 Cr.364.80 Cr.
Total Revenue21439.10 Cr.18972.20 Cr.17460 Cr.15385.10 Cr.
Total Operating Expenses18287.50 Cr.15675.20 Cr.14528.70 Cr.13417.60 Cr.
Cost of Revenue10055.10 Cr.8664.50 Cr.8059.10 Cr.7042.10 Cr.
Total Other Income Expense Net78.20 Cr.-655.70 Cr.-1128.10 Cr.276.80 Cr.
Discontinued OperationsNoneNoneNoneNone
Net Income from Continuous Ops.2356.80 Cr.1723.80 Cr.1949.80 Cr.1879.50 Cr.
Net Income Applicable to Common Shares2356.80 Cr.1723.80 Cr.1949.80 Cr.1879.50 Cr.

Balance Sheet

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Intangible Assets2724.60 Cr.3564.80 Cr.2765.90 Cr.4436.70 Cr.
Capital Surplus928 Cr.888.70 Cr.849.50 Cr.821.10 Cr.
Total Liabilities10612.70 Cr.9242.90 Cr.7725.30 Cr.8523 Cr.
Stock Holder Equity19052.70 Cr.17306.20 Cr.15498.80 Cr.14019.70 Cr.
Minority Interest0000
Other Liabilities4417.10 Cr.1487.70 Cr.1281.90 Cr.920.60 Cr.
Total Assets29665.40 Cr.26549.10 Cr.23224.10 Cr.22542.70 Cr.
Common Stock83.20 Cr.83.20 Cr.83.10 Cr.83 Cr.
Retained Earnings17646.70 Cr.15734.90 Cr.14424.70 Cr.12864.60 Cr.
Other Liabilities253.90 Cr.273.90 Cr.313.50 Cr.353 Cr.
Good Will441.80 Cr.456.80 Cr.399.40 Cr.390.20 Cr.
Treasury Stock394.80 Cr.599.40 Cr.141.50 Cr.251 Cr.
Other Assets1372.90 Cr.1158.20 Cr.1479.50 Cr.522.70 Cr.
Cash1485.20 Cr.1482.90 Cr.205.30 Cr.222.80 Cr.
Current Liabilities9784.20 Cr.8339.10 Cr.7281.40 Cr.5970 Cr.
Long Term Asset Charges1278.10 Cr.1063 Cr.1221.40 Cr.416.80 Cr.
Short Long Term Debt00378.30 Cr.419.90 Cr.
Other Stockholder Equity554.90 Cr.796.10 Cr.242.10 Cr.304.50 Cr.
Property Plant Equipment6216.90 Cr.5711.10 Cr.5233.20 Cr.5408.80 Cr.
Total Cur. Assets18110.60 Cr.14824.90 Cr.13037 Cr.11450.10 Cr.
Long Term Investments798.60 Cr.833.30 Cr.309.10 Cr.334.20 Cr.
Net Tangible Assets15886.30 Cr.13284.60 Cr.12333.50 Cr.9192.80 Cr.
Short Term Investments2951.30 Cr.1974.40 Cr.2368.70 Cr.2252.90 Cr.
Net Receivables7004.90 Cr.5445.60 Cr.5730.90 Cr.4563.20 Cr.
Long Term Debt574.60 Cr.380 Cr.02144.80 Cr.
Inventory5088.40 Cr.4541.20 Cr.3506.60 Cr.3357.90 Cr.
Accounts Payable2557.20 Cr.1269.60 Cr.1074.50 Cr.1029.60 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account